Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 500 of 520 entries
View as:

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03874325 Org: User:
Start: 04/26/19 End: 01/06/21 Due: 01/06/22

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01054144 Org: User:
Start: 01/14/10 End: 11/24/20 Due: 11/24/21

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT00660400 Org: User:
Start: 03/31/08 End: 06/30/14 Due: 06/30/15

Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT04275557 Org: User:
Start: 02/18/20 End: 06/30/27 Due: 06/30/28

Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT06476548 Org: User:
Start: 06/12/24 End: 08/26/25 Due: 08/26/26

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT05271630 Org: User:
Start: 04/20/22 End: 12/31/26 Due: 12/31/27

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

Phase: N/A Priority: Normal
NCT ID: NCT06235281 Org: User:
Start: 01/18/24 End: 09/01/29 Due: 09/01/30

Smoking Cessation for Cervical Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT02157610 Org: User:
Start: 01/31/15 End: 08/31/21 Due: 08/31/22

Genetic Counseling for Breast Cancer Survivors (GC for BC)

Phase: N/A Priority: Normal
NCT ID: NCT02451735 Org: User:
Start: 07/27/12 End: 07/12/19 Due: 07/12/20

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05526989 Org: User:
Start: 12/28/22 End: 11/30/27 Due: 11/30/28

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02989870 Org: User:
Start: 03/27/17 End: 10/15/18 Due: 10/15/19

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Phase: N/A Priority: Normal
NCT ID: NCT01008527 Org: User:
Start: 10/31/09 End: 09/30/15 Due: 09/30/16

Motivating a Spectrum of Cancer Patients to Quit Smoking

Phase: N/A Priority: Normal
NCT ID: NCT04914000 Org: User:
Start: 06/14/21 End: 06/02/22 Due: 06/02/23

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02292173 Org: User:
Start: 02/18/15 End: 01/31/21 Due: 01/31/22

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

Phase: N/A Priority: Normal
NCT ID: NCT01496976 Org: User:
Start: 03/30/12 End: 09/11/24 Due: 09/11/25

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03290079 Org: User:
Start: 12/15/17 End: 05/13/24 Due: 05/13/25

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03501368 Org: User:
Start: 06/27/18 End: 01/31/26 Due: 01/31/27

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT00831766 Org: User:
Start: 06/25/09 End: 11/16/20 Due: 11/16/21

Smoking Relapse-Prevention Intervention for Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01630161 Org: User:
Start: 01/04/12 End: 11/18/20 Due: 11/18/21

Randomized Controlled Trial of Endoscopic Dilation: Triamcinolone Injection

Phase: N/A Priority: Normal
NCT ID: NCT01873573 Org: User:
Start: 07/18/13 End: 10/16/17 Due: 10/16/18

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Phase: N/A Priority: Normal
NCT ID: NCT00005622 Org: User:
Start: 05/31/96 End: 07/31/09 Due: 07/31/10

Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)

Phase: N/A Priority: Normal
NCT ID: NCT00005626 Org: User:
Start: 02/28/98 End: 11/30/03 Due: 11/30/04

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00006033 Org: User:
Start: 06/30/00 End: 06/30/04 Due: 06/30/05

Natural History of HPV Infection in Men: The HIM Study

Phase: N/A Priority: Normal
NCT ID: NCT00786760 Org: User:
Start: 06/14/05 End: 10/31/14 Due: 10/31/15

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06238921 Org: User:
Start: 12/19/24 End: 02/28/27 Due: 02/28/28